-transparent.png){kind=logo}
In this review, we examine the data evaluating the role of adjuvant therapy with antiarrthymic drugs (AADs) in chronic suppression of ventricular tachyarrhythmias in the patient with an ICD. It must be noted that all uses of AADs for this indication represent "off-label" prescription. No AAD is approved by the Food and Drug Administration (FDA) specifically as a therapy to reduce ICD shocks.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Michael S Zawaneh, and
Bruce S Stambler
April 1997,
Zeitschrift fur Kardiologie,
Michael S Zawaneh, and
Bruce S Stambler
June 2008,
Ugeskrift for laeger,
Michael S Zawaneh, and
Bruce S Stambler
February 2020,
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,
Michael S Zawaneh, and
Bruce S Stambler
February 1993,
Cardiology clinics,
Michael S Zawaneh, and
Bruce S Stambler
September 1995,
The Medical clinics of North America,
Michael S Zawaneh, and
Bruce S Stambler
December 2022,
Scandinavian cardiovascular journal : SCJ,
Michael S Zawaneh, and
Bruce S Stambler
November 1988,
Journal of clinical pharmacology,
Michael S Zawaneh, and
Bruce S Stambler
June 1983,
The New England journal of medicine,
Michael S Zawaneh, and
Bruce S Stambler
November 1981,
Circulation,
Michael S Zawaneh, and
Bruce S Stambler
November 1993,
European heart journal,
